Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Hyoscine Butylbromide 10mg Formulations
NCT02516098Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of hyoscine butylbromide in gastrointestinal spasm (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum Observed Plasma Concentration and Area Under the Curve Time Zero to Last Quantifiable Concentration. Started Oct 2015; status: completed.
02
Drugs
hyoscine butylbromide
03
Conditions
gastrointestinal spasm
Beyond the preview
Go deeper on NCT02516098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02516098.